Icon Group delivers world-leading, integrated healthcare operating in Australia, New Zeaand, Singapore, Hong Kong, Mainland China, Malaysia and the United Kingdom.
The Group brings together all aspects of care from day oncology to radiation oncology, chemotherapy compounding, research, and pharmacy for the benefit of patients. We are built on a strong but simple vision – to deliver the best care possible to as many people as possible, as close to home as possible.
Oncology day hospital – Our day oncology division is Australia’s largest private provider of day oncology and haematology with centres nationally, and in Singapore, Hong Kong and New Zealand.
Radiation oncology – Our radiation oncology division was formed via the acquisition of four key radiation oncology businesses. We have world-class radiation oncology services across our international footprint equipped with the latest in technology and treatment techniques.
Chemotherapy compounding – Slade Health is one of Australia’s largest chemotherapy compounders delivering over 1000,000 infusions annually with a growing reach overseas.
Pharmacy management – for Epic Pharmacy and Slade Pharmacy, Australia's leading pharmaceutical supply businesses for the hospital, oncology sectors.
Research and clinical trials – deliver Australia's largest private cancer clinical trials program with a growing global reach. Icon conducts trials across medical oncology, haematology, radiation oncology and pharmacy, including investigator initiated trials.
This comprehensive end-to-end service model enables us to work as one multidisciplinary team to deliver exceptional care. With a strong focus on innovation and investment in technology based solutions, as well as global partnerships with peak industry leaders such as Varian and the Union for International Cancer Control [UICC], Icon is truly at the forefront of cancer treatment.
Industry
Hospitals and Health Care
HQ Location
level 1, 22 Cordelia St, South Brisbane
Brisbane, QLD 4101, AU
Keywords
Cancer careradiation oncologymedical oncologypharmacyhealthcarecompoundingoncologycancer researchclinical trialshaematology